Methods of Treating Giant Cell Arteritis With Anti-TNF Alpha Antibodies
AssigneesNew York University, Janssen Biotech, Inc.
InventorsJunming Le, Jan T. Vilcek, Peter E. Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel
Life of this patent
Estimating the term…
Abstract
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Claims16
A method of treating giant cell arteritis in a human in need thereof, comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα chimeric antibody or antigen-binding fragment thereof for a sufficient period of time to treat the giant cell arteritis, wherein said anti-TNFα chimeric antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα and (ii) binds to a neutralizing epitope of human TNFα with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
Dependencies are inferred from the claim text.